NEW YORK (GenomeWeb) – The Cas9 nuclease from Staphylococcus aureus can be used to edit genomes as efficiently as Cas9 from Streptococcus pyogenes but at a smaller size, enabling CRISPR methods for in vivo applications that could eventually include therapeutic use, researchers reported today in a study published in Nature.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.